Abstract
Factor Xa (fXa) is a serine protease that plays a critical role in the blood coagu-lation process and qualifies as an attractive target for finding new antithrombotics. In the case of fXa several structure based drug design strategies have been followed because of the difficulty in growing fXa co-crystals routinely. This has led to the use of surrogate proteins such as trypsin. Factor Xa inhibitors for which the binding mode has been determined experimentally or modeled are described in this review. The inhibitors are divided into three fragments: a P1 group, a central scaffold and a P4 group. In this review, interactions in each sub-site of fXa with various inhibitor fragments have been examined at the molecular level and were shown to bind, in most cases, independently of the rest of the molecule. Knowledge of the 3D structure of the binding mode of ligands to target proteins has been successfully applied in designing fXa inhibitors with enhanced specificity, affinity and has provided hints to modulate the physico-chemical properties of the small molecule ligand.
Keywords: serine protease
Current Topics in Medicinal Chemistry
Title: The Use of 3D Structural Data in the Design of Specific Factor Xa Inhibitors
Volume: 1 Issue: 2
Author(s): Sebastien Maignan and Vincent Mikol
Affiliation:
Keywords: serine protease
Abstract: Factor Xa (fXa) is a serine protease that plays a critical role in the blood coagu-lation process and qualifies as an attractive target for finding new antithrombotics. In the case of fXa several structure based drug design strategies have been followed because of the difficulty in growing fXa co-crystals routinely. This has led to the use of surrogate proteins such as trypsin. Factor Xa inhibitors for which the binding mode has been determined experimentally or modeled are described in this review. The inhibitors are divided into three fragments: a P1 group, a central scaffold and a P4 group. In this review, interactions in each sub-site of fXa with various inhibitor fragments have been examined at the molecular level and were shown to bind, in most cases, independently of the rest of the molecule. Knowledge of the 3D structure of the binding mode of ligands to target proteins has been successfully applied in designing fXa inhibitors with enhanced specificity, affinity and has provided hints to modulate the physico-chemical properties of the small molecule ligand.
Export Options
About this article
Cite this article as:
Maignan Sebastien and Mikol Vincent, The Use of 3D Structural Data in the Design of Specific Factor Xa Inhibitors, Current Topics in Medicinal Chemistry 2001; 1 (2) . https://dx.doi.org/10.2174/1568026013395461
DOI https://dx.doi.org/10.2174/1568026013395461 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chalcones: As Potent α-amylase Enzyme Inhibitors; Synthesis, <i>In Vitro</i>, and <i>In Silico</i> Studies
Medicinal Chemistry Heteroaromatization with 4-Phenyldiazenyl-1-naphthol. Part IV: Synthesis of Some New Heterocyclic Compounds with Potential Biological Activity
Current Organic Synthesis Therapeutic Targets and Computational Approaches on Drug Development for COVID-19
Current Topics in Medicinal Chemistry Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Steroid Hormone Binding Receptors: Application of Homology Modeling, Induced Fit Docking, and Molecular Dynamics to Study Structure- Function Relationships
Current Topics in Medicinal Chemistry Respiratory Syncytial Virus is the Most Common Causative Agent of Viral Bronchiolitis in Young Children: An Updated Review
Current Pediatric Reviews β-Lactone Derivatives and Their Anticancer Activities: A Short Review
Current Topics in Medicinal Chemistry Chalcone and Curcumin Derivatives: A Way Ahead for Malarial Treatment
Mini-Reviews in Medicinal Chemistry Histamine H4 Receptor: A Novel Target for Inflammation Therapy
Mini-Reviews in Medicinal Chemistry Interplay between SARS-CoV-2 and Cancer: Plausible Risk Factors, Cellular Immune Responses, Cancer Directed Therapy- Current Challenges
Infectious Disorders - Drug Targets From Drug Target to Leads-Sketching A Physicochemical Pathway for Lead Molecule Design In Silico
Current Pharmaceutical Design A Comparative Adsorption Study on Low-cost Synthetic, Nano and Doped ZnO for the Removal of Copper Surfactants Urea Complexes: Equilibrium, Kinetics, and Thermodynamics
Nanoscience & Nanotechnology-Asia Developments of Combretastatin A-4 Derivatives as Anticancer Agents
Current Medicinal Chemistry COVID-19: How Nuclear Medicine Can Provide A Differential Diagnosis In A Very Dubious Case
Coronaviruses Recent Development in [1,4]Benzodiazepines as Potent Anticancer Agents: A Review
Mini-Reviews in Medicinal Chemistry Selective Histone Deacetylase Inhibitors with Anticancer Activity
Current Topics in Medicinal Chemistry The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry Discovery of Potential Inhibitors of the Receptor-binding Domain (RBD) of Pandemic Disease-causing SARS-CoV-2 Spike Glycoprotein from Triphala Through Molecular Docking
Current Chinese Chemistry